Polymerases, compositions, and methods of use

US2024141427A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2024141427-A1
Application numberUS-202318373620-A
CountryUS
Kind codeA1
Filing dateSep 27, 2023
Priority dateSep 30, 2022
Publication dateMay 2, 2024
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain low error rate, low phasing rate, or increased incorporation rate for a second generation ffN under reduced incorporation times, as well as methods and kits using the same.

First claim

Opening claim text (preview).

1 . An altered archaeal Family B DNA polymerase, wherein the altered archaeal Family B DNA polymerase comprises at least one an amino acid substitution mutation at a position functionally equivalent to an amino acid in a reference archaeal Family B DNA polymerase of SEQ ID NO:1, and the altered archaeal Family B DNA polymerase is capable of incorporating a modified nucleotide comprising a 3′-OH acetal blocking group or a 3′-OH thiocarbamate blocking group at (i) a lower error rate, (ii) a lower phasing rate, or both (i) and (ii), compared to SEQ ID NO:1; wherein the amino acid is at position Phe405 wherein the amino acid is at position Glu580, and a second amino acid is at position Phe405; wherein the amino acid is at position Glu580, and a second amino acid is at position Val485; wherein the amino acid is at position Glu580, and a second amino acid is at position Trp516; wherein the amino acid is at position Glu580, and a second amino acid is at position Leu571; wherein the amino acid is at position Glu580, and a second amino acid is at position Leu571; wherein the amino acid is at position Glu580, a second amino acid is at position Ala408, and a third mutation is at position Ile410; wherein the amino acid is at position Glu580, and a second amino acid is at position Ala408; wherein the amino acid is at position Glu580, and a second amino acid is at position Phe405; wherein the amino acid is at position Glu580, and a second amino acid is at position Ile410; wherein the amino acid is at position Phe405, and a second amino acid is at position Val485; wherein the amino acid is at position Phe405, a second amino acid is at position Val485, and a third mutation is at position Ala408; wherein the amino acid is at position Phe405, and a second amino acid is at position Ile410; wherein the amino acid is at position Phe140, and a second amino acid is at position Ser407; wherein the amino acid is at position Leu403, a second amino acid is at position Ala408, a third amino acid is at position Ile410, and a fourth amino acid is at position Gly497; wherein the amino acid is at position Phe405, a second amino acid is at position Ile410, a third amino acid is at position Ile412, a fourth amino acid is at position Thr514, and a fifth amino acid is at position Ile521; or wherein the amino acid is at position Phe405, a second amino acid is at position Ala408, a third amino acid is at position Ile410, a fourth amino acid is at position Ile412, a fifth amino acid is at position Thr514, and a sixth amino acid is at position Ile521. 2 - 96 . (canceled) 97 . An altered archaeal Family B DNA polymerase comprising the amino acid sequence of any one of SEQ ID NOs:2-8 or any one of SEQ ID NOs: 16-32. 98 . The altered archaeal Family B DNA polymerase of claim 1 , wherein the polymerase comprises reduced exonuclease activity as compared to SEQ ID NO:9. 99 . A nucleic acid molecule encoding a DNA polymerase as defined in claim 1 . 100 . An expression vector comprising the nucleic acid molecule of claim 99 . 101 . A host cell comprising the vector of claim 100 . 102 . A method for incorporating modified nucleotides into a polynucleotide complementary to a target nucleic acid comprising allowing the following components to interact: (i) the altered archaeal Family B DNA polymerase of claim 1 , (ii) a DNA template; and (iii) a nucleotide solution. 103 . The method of claim 102 , wherein the DNA template comprises a clustered array. 104 . A kit for performing a nucleotide incorporation reaction comprising: the altered archaeal Family B DNA polymerase of claim 1 , and a solution comprising second generation fully functional nucleotides. 105 . The kit of claim 104 , wherein the second generation fully functional nucleotides comprise a detectable label. 106 . The kit of claim 104 , wherein the second generation fully functional nucleotides have been modified at the 3′ sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3′ hydroxyl group. 107 . The kit of claim 106 , wherein the second generation fully functional nucleotides comprise a modified nucleotide molecule comprising a purine or pyrimidine base and a deoxyribose sugar moiety comprising a removable 3′-OH acetal blocking group or a 3′-OH thiocarbamate blocking group attached to the 3′ carbon of the deoxyribose sugar moiety. 108 . The kit of claim 107 , wherein the 3′-OH acetal blocking group has the structure wherein the *** indicates the attachment point of the 3′-OH acetal blocking group to the 3′ carbon of the modified nucleotide sugar. 109 . The kit of claim 104 , wherein the second generation fully functional nucleotides comprise a nucleotide molecule comprising a purine or pyrimidine base attached to a detectable label via a cleavable linker. 110 . The kit of claim 109 , wherein the detectable label comprises a fluorescent label. 111 . The kit of claim 109 , wherein the cleavable linker is selected from the group consisting of wherein Z is —O—CH 2 —CH═CH 2 ; n is an integer of 1, 2, 3, 4 or 5; * indicates the attachment point of the cleavable linker to the purine or pyrimidine base; and ** indicates the attachment point of the cleavable linker to the detectable label. 112 . The kit of claim 104 , further comprising one or more DNA template molecules and/or primers.

Assignees

Inventors

Classifications

  • DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

  • C12Q1/6874Primary

    involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

  • C12N9/1252Primary

    DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase · CPC title

  • Genes encoding for enzymes or proenzymes · CPC title

  • of the backbone · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2024141427A1 cover?
Presented herein are altered polymerase enzymes for improved incorporation of nucleotides and nucleotide analogues, in particular altered polymerases that maintain low error rate, low phasing rate, or increased incorporation rate for a second generation ffN under reduced incorporation times, as well as methods and kits using the same.
Who is the assignee on this patent?
Illumina Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6874. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu May 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).